Shopping Cart 0
Cart Subtotal
USD 0

University of Washington - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

University of Washington (UoW) is an educational institution that provides undergraduate, postgraduate and master's degrees. The university provides courses in the areas of accounting, aeronautics, applied mathematics, bioengineering, business, social sciences, science, law, medicine, and public affairs. It also offers services in nursing, health services, astronomy, computer science, molecular biotechnology and oceanography, among others. UoW operates through its institutions such as College of Engineering, School of Dentistry, College of Architecture and Urban Planning, School of Pharmacy, School of Public Health and Community Medicine, School of Nursing and School of Medicine, among others. UoW is headquartered in Seattle, Washington, the US.

University of Washington-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

University of Washington, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

University of Washington, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

University of Washington, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

University of Washington, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

University of Washington, Medical Devices Deals, 2012 to YTD 2018 11

University of Washington, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

University of Washington, Pharmaceuticals & Healthcare, Deal Details 16

Venture Financing 16

Nexgenia Raises USD0.5 Million in Seed Financing Round 16

Faraday Pharma Raises USD3.7 Million in Series A Financing 17

Partnerships 19

C2N Diagnostics Expands Licensing Agreement with Washington University School of Medicine 19

Mallinckrodt Enters into Research Partnership with Washington University 20

Cerveau Technologies Enters into Agreement with Washington University School of Medicine 21

MedImmune Enters into Agreement with Washington University School of Medicine 22

Pfizer Enters into Agreement with Washington University in St. Louis 23

GenVec Enters into Agreement with Washington University in St. Louis 24

MaxCyte Enters into Agreement with Washington University in St Louis 25

Solid Biosciences Enters into Agreement with University of Washington 26

Turing Pharma Enters into Partnership with Washington University 27

LEO Pharma Enters into Agreement with Washington University School of Medicine 28

Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 29

Novo Nordisk Enters into Research Agreement with UW Medicine 30

Johnson & Johnson Innovation Enters into Research Agreement with Washington University 31

GenVec Enters into Agreement with Washington University at St. Louis 32

Kineta, KPI Therapeutics Enter into Partnership with UW Medicine and University of Washington 33

BioMotiv, University of California San Francisco and University of Washington Center for Commercialization Form Joint Venture 34

OncoSec Medical Enters into Research Agreement with University of Washington 35

Licensing Agreements 36

Q BioMed to Expand Option Agreement with Washington University 36

Disarm Therapeutics Enters into Licensing Agreement with Washington University in St. Louis 37

Canopy Biosciences Enters into Licensing Agreement with Washington University in St. Louis and Johns Hopkins University 38

Precision Virologics Enters into Licensing Agreement with Washington University 39

PvP Biologics Enters into Licesning Agreement with University of Washington 40

Denali Therapeutics Enters into Licensing Agreement with Washington University School of Medicine 41

Accuronix Therapeutics Enters into Licensing Agreement with Washington University in St. Louis 42

Optikira Enters into Licensing Agreement with University of California, San Francisco and University of Washington 43

Avalanche Biotech Enters into Licensing Agreement with University of Washington 44

ViewPoint Therapeutics Receives Technology Rights from University of Michigan and Washington University 45

Sage Therapeutics Enters Into Licensing Agreement With Washington University To Develop Gaba Receptor Small Molecules 46

Stella Therapeutics Enters into Licensing Agreement with University of Washington and University of Montana 47

ChromaDex Amends Licensing Agreement With Washington University For Nicotinamide Riboside 48

GenetikSignal Enters Into Licensing Agreement With University Of Washington 49

Stella Therapeutics Enters into Licensing Agreement with University of Washington 50

Fimbrion Therapeutics Enters into Licensing Agreement with Washington University 51

Nexgenia Enters into Licensing Agreement with University of Washington 52

University of Washington-Key Competitors 53

University of Washington-Key Employees 54

University of Washington-Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Joint Venture 56

Recent Developments 58

Government and Public Interest 58

Sep 19, 2018: NIH funds study to prevent, treat HIV among adolescents in poor countries 58

Sep 19, 2018: NIH announces awards for behavioral research on OUD prevention and treatment 59

Sep 06, 2018: Smith awarded USD 8.5 million to compare treatments for recurrent bladder cancer 60

Aug 21, 2018: PCORI Board approves USD 85 million to support new studies on opioids, cancer and other high-burden conditions 61

Aug 10, 2018: Icahn Institute partners in USD 6.5 million NIH award to advance precision medicine and bioengineering capabilities 62

Aug 07, 2018: NIH awards University of Washington, partner institutions USD 6.5M for reusable, reproducible biomedical modeling 63

Jul 24, 2018: NIH expands program that conducts large-scale clinical trials in real-world settings 64

Jul 18, 2018: St. Baldrick's foundation announces USD 19.1 million in grants to fund lifesaving childhood cancer research 65

Jul 10, 2018: ARMADA Launches Global Attack on Antibiotic Resistance 66

Jun 28, 2018: Kidney Disease Patients' Experience Of Care And Illness Can Take A Large Emotional Toll 67

May 14, 2018: Genetic fixer-uppers may help predict bladder cancer prognosis 68

May 03, 2018: Early HIV treatment key to avoiding brain atrophy 70

Apr 17, 2018: National MS Society Commits USD 14.2 Million to New Research to Stop Multiple Sclerosis, Restore Function and End MS Forever 71

Dec 14, 2017: Computational strategies overcome obstacles in peptide drug development 72

Nov 14, 2017: Targeted therapies push metastatic prostate cancer in new directions 74

Oct 27, 2017: Johns Hopkins Partnering with Other Institutions to Create a National Center for Health Data 76

Oct 18, 2017: German Research Advances in Cancer and Blood Disorders Reported in Human Gene Therapy 77

Oct 02, 2017: TSRI Researchers Join National Digital Health Informatics Collaborative 78

Sep 01, 2017: Researchers create designer stem cells 79

Aug 10, 2017: TSRL Awarded Two NIH Grants to Develop Therapeutics for Multi-Drug Resistant Infections 80

Jun 20, 2017: UW-led scientists 'closing the gap' on malaria in India 81

Jun 19, 2017: Study ID's potential new target to treat viral infections 83

Jan 30, 2017: Monitoring Post-Mortem Gene Transcription in Mice and Zebrafish 84

Product News 86

Jun 22, 2018: Research team discovers drug compound that stops cancer cells from spreading 86

Apr 17, 2017: New step towards the treatment of myotubular myopathy: gene therapy restores strength and prolongs lives in affected dogs 88

Feb 05, 2018: Patients with Kidney Disease Receiving Heart Defibrillators at Greater Risk of Hospitalization 89

Jan 16, 2018: Researchers program biomaterials with 'logic gates' that release therapeutics in response to environmental triggers 90

Other Significant Developments 92

Sep 10, 2018: New method of pinpointing cancer mutations could lead to more targeted treatments 92

Sep 04, 2018: Tailoring behavioral therapy for depression, obesity based on how the brain responds 94

May 28, 2018: Scientists expand genetic screening to include rare medical disorders 95

Appendix 96

Methodology 96

About GlobalData 96

Contact Us 96

Disclaimer 96


List Of Figure

List of Figures

University of Washington, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

University of Washington, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

University of Washington, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

University of Washington, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

University of Washington, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

University of Washington, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

University of Washington, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

University of Washington, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

University of Washington, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

University of Washington, Pharmaceuticals & Healthcare, Key Facts 2

University of Washington, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

University of Washington, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

University of Washington, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

University of Washington, Deals By Therapy Area, 2012 to YTD 2018 10

University of Washington, Medical Devices Deals, 2012 to YTD 2018 11

University of Washington, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Nexgenia Raises USD0.5 Million in Seed Financing Round 16

Faraday Pharma Raises USD3.7 Million in Series A Financing 17

C2N Diagnostics Expands Licensing Agreement with Washington University School of Medicine 19

Mallinckrodt Enters into Research Partnership with Washington University 20

Cerveau Technologies Enters into Agreement with Washington University School of Medicine 21

MedImmune Enters into Agreement with Washington University School of Medicine 22

Pfizer Enters into Agreement with Washington University in St. Louis 23

GenVec Enters into Agreement with Washington University in St. Louis 24

MaxCyte Enters into Agreement with Washington University in St Louis 25

Solid Biosciences Enters into Agreement with University of Washington 26

Turing Pharma Enters into Partnership with Washington University 27

LEO Pharma Enters into Agreement with Washington University School of Medicine 28

Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 29

Novo Nordisk Enters into Research Agreement with UW Medicine 30

Johnson & Johnson Innovation Enters into Research Agreement with Washington University 31

GenVec Enters into Agreement with Washington University at St. Louis 32

Kineta, KPI Therapeutics Enter into Partnership with UW Medicine and University of Washington 33

BioMotiv, University of California San Francisco and University of Washington Center for Commercialization Form Joint Venture 34

OncoSec Medical Enters into Research Agreement with University of Washington 35

Q BioMed to Expand Option Agreement with Washington University 36

Disarm Therapeutics Enters into Licensing Agreement with Washington University in St. Louis 37

Canopy Biosciences Enters into Licensing Agreement with Washington University in St. Louis and Johns Hopkins University 38

Precision Virologics Enters into Licensing Agreement with Washington University 39

PvP Biologics Enters into Licesning Agreement with University of Washington 40

Denali Therapeutics Enters into Licensing Agreement with Washington University School of Medicine 41

Accuronix Therapeutics Enters into Licensing Agreement with Washington University in St. Louis 42

Optikira Enters into Licensing Agreement with University of California, San Francisco and University of Washington 43

Avalanche Biotech Enters into Licensing Agreement with University of Washington 44

ViewPoint Therapeutics Receives Technology Rights from University of Michigan and Washington University 45

Sage Therapeutics Enters Into Licensing Agreement With Washington University To Develop Gaba Receptor Small Molecules 46

Stella Therapeutics Enters into Licensing Agreement with University of Washington and University of Montana 47

ChromaDex Amends Licensing Agreement With Washington University For Nicotinamide Riboside 48

GenetikSignal Enters Into Licensing Agreement With University Of Washington 49

Stella Therapeutics Enters into Licensing Agreement with University of Washington 50

Fimbrion Therapeutics Enters into Licensing Agreement with Washington University 51

Nexgenia Enters into Licensing Agreement with University of Washington 52

University of Washington, Key Competitors 53

University of Washington, Key Employees 54

University of Washington, Subsidiaries 55

University of Washington, Joint Venture 56

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

University of Washington, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.